SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as investors focus on potential catalyst opportunities involving GLP-1 and peptide distribution, despite ongoing debates about the stock's volatility and recent C-suite share sales. The community remains heavily divided, with bulls highlighting long-term platform growth and market share gains, while bears continue to scrutinize the high short interest and technical pressure.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending following the announcement of a DARPA contract and a successful photonic interconnect milestone that demonstrates the feasibility of networked quantum systems. Investors and community members are actively debating the company's long-term potential as a quantum infrastructure leader versus concerns over its current path to profitability and high volatility.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is generating significant social media buzz as traders debate its speculative recovery potential amid broader volatility in the quantum computing sector. While bullish sentiment is fueled by the company's established commercial annealing platform and strategic defense collaborations, bears are pointing to the stock's lack of consistent profitability and intensifying competition from gate-model advancements as reasons for caution.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors monitor record-high short interest and anticipation surrounding the Northern Data acquisition, which is expected to significantly boost the company's cloud and AI infrastructure capacity. The community is focused on the strategic financial commitment from Tether and the potential for a substantial short squeeze as traders weigh the company's long-term growth prospects against ongoing market volatility.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple is trending as investors react to a flurry of reports regarding real-world adoption, including integration with major payment platforms and potential legislative breakthroughs with the Clarity Act. While the community is actively debating the coin's utility-driven long-term potential versus concerns over supply dilution, sentiment remains polarized between those accumulating at current levels and those frustrated by its sideways price action.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood (HOOD) is seeing a surge in investor sentiment and trading activity driven by news that regulators are eliminating the pattern day trading rule, a move seen as a major catalyst for retail engagement and increased platform revenue. The community is actively debating the stock's potential to retest all-time highs as traders focus on the impact of reduced barriers to entry for smaller accounts and broader fintech momentum.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is facing significant bearish sentiment and selling pressure as investors express deep frustration over the company's persistent underperformance relative to broader market indices like the S&P 500 and Nasdaq. The community is actively debating the company's massive cash reserves and recent share buybacks, while growing increasingly critical of Warren Buffett's leadership, his controversial relationship with Bill Gates, and the perceived inability to identify new growth opportunities in the current economic landscape.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending as investors react to a mix of new product launches, such as instant settlement features, and ongoing volatility driven by aggressive short-seller commentary and analyst coverage. Community discourse is sharply divided between bulls anticipating a technical breakout leading into earnings and skeptical voices focused on long-term valuation concerns and historical price pressure.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is surging after the SEC approved the elimination of the long-standing pattern day trading rule, a structural catalyst that investors expect will drive significant increases in trading volume and platform engagement. The community is buzzing over the stock's double-catalyst setup, which also includes the recent termination of a dilutive financing agreement, leading many to compare its growth trajectory and undervalued status to other major fintech players.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is facing intense volatility as investors debate the company's ability to hit commercial milestones amidst a broader rotation out of speculative quantum stocks. While some traders are attempting to play the volatility via short squeezes and technical setups, community discourse remains deeply divided over the gap between the firm's long-term quantum infrastructure goals and its current revenue generation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Citigroup Analyst Says

Citigroup boosted their price objective on shares of Ligand Pharmaceuticals from $276.00 to $282.00 and gave the stock a "buy" rating in a report on Wednesday...

Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 12-Month High Following Analyst Upgrade

Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 52-Week High Following Analyst Upgrade...

Ligand Pharmaceuticals (NASDAQ:LGND) Given New $243.00 Price Target at HC Wainwright

HC Wainwright upped their price objective on Ligand Pharmaceuticals from $239.00 to $243.00 and gave the company a "buy" rating in a research report on Tuesday...

<ul class="summary-bullets"><li>On Monday, the U.S. FDA approved Filspari to reduce proteinuria in patients with focal segmental glomerulosclerosis, a rare kidney disorder.</li><li>The company estimates that over 30,000 people in the U.S. with FSGS without nephrotic syndrome could be eligible for the treatment.</li><li>Citi does not see a commercial setback despite a narrower label, according to The Fly.</li></ul>Shares of Travere Therapeutics (TVTX) surged more than 40% in pre-market trading on Tuesday as bullish analyst reactions followed the U.S. Food and Drug Administration (FDA) approval of the company’s Filspari for a rare kidney disorder, making it the first approved treatment for the condition.If the premarket levels hold after the opening bell, <a href="https://stocktwits.com/symbol/TVTX">TVTX shares</a> would surge to their highest since May 2005.<h2 class="st-heading-2">Filspari Becomes The Only Approved FSGS Treatment</h2>On Monday, the U.S. FDA approved Filspari to reduce proteinuria in patients with focal segmental glomerulosclerosis (FSGS). FSGS is a serious condition that causes protein leakage in urine, leading to progressive kidney damage and potential failure. The company estimates that over 30,000 people in the U.S. with FSGS without nephrotic syndrome could be eligible for the treatment.The decision follows a delayed review prompted by the FDA's request for additional data. Approval was supported by late-stage trial results showing Filspari reduced proteinuria by 48% over 108 weeks.Brokerages turned bullish on Travere Therapeutics following the FDA approval. Canaccord raised its price target to $56 from $47 and maintained a ‘Buy’ rating, according to The Fly, projecting peak sales of $547 million for the drug by 2032.Citi analyst Yigal Nochomovitz increased the firm’s price target to $53 from $48, keeping a ‘Buy’ rating. Citi said the approval in FSGS supports the increased target, adding that the narrower label is not seen as a commercial setback. Bank of America also lifted its target to $49 from $44 and reiterated a ‘Buy’ rating on the stock.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours. Messages on the platform increased a whopping 3,200% during the same period, according to Stocktwits data.&nbsp;&nbsp;One user expects “swift uptake for this medicine.”<stembedurl>https://stocktwits.com/pblegend66/message/650201899</stembedurl>Year-to-date, the stock has slid around 21%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment

Canaccord projected peak sales of $547 million for the drug by 2032, according to The Fly.

Equity

<ul><li>The agency approved the drug in adult and pediatric patients aged 8 years and older.</li><li>Travere expects that there are at least 30,000 people in the U.S. with focal segmental glomerulosclerosis but without nephrotic syndrome. &nbsp;</li><li>Filspari was previously greenlit by the FDA for the treatment of IgA nephropathy.</li></ul>Travere Therapeutics, Inc. (TVTX) said on Monday that the U.S. Food and Drug Administration has approved its Filspari to reduce proteinuria in some patients with focal segmental glomerulosclerosis (FSGS), making it the first FDA-approved drug for the indication.The agency approved the drug in adult and pediatric patients aged 8 years and older. Travere expects that there are at least 30,000 people in the U.S. with focal segmental glomerulosclerosis but without nephrotic syndrome.Filspari was previously greenlit by the FDA for the treatment of IgA nephropathy, a chronic autoimmune kidney disease characterized by the abnormal accumulation of immunoglobulin A (IgA) antibodies in the kidneys' filtering units.<h2 class="st-heading-2">Fresh Approval</h2>While the FDA was previously expected to decide on Travere’s application by January, it pushed it to April after requesting additional information to assess Filspari’s clinical benefit. The company submitted responses, and the agency determined that the responses constitute a major amendment to the application, and extended the review timeline.Filspari was approved in the new indication based on data from a late stage trial where FSGS patients without nephrotic syndrome who were treated with Filspari experienced a 48% reduction in proteinuria from baseline to week 108 compared to 27% for those treated with irbesartan.FSGS is a rare and serious kidney disorder driven by proteinuria or protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. The disease leads to progressive kidney function loss and kidney failure.While TVTX edged 0.2% lower after hours, shares of Ligand Pharmaceuticals (LGND), with which Travere has a licensing agreement for Sparsentan, sold under the Filspari brand, rose 3% at the time of writing.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around TVTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/TVTX">TVTX</a> has gained 107% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/aal-stock-advances-after-hours-following-report-of-ual-ceo-combining-his-past-and-present-companies/cZJ8WmWRIuC">AAL Stock Advances After-Hours Following Report Of UAL CEO Combining His Past And Present Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease

The FDA approved Filspari to reduce proteinuria in some patients with focal segmental glomerulosclerosis.

<ul class="summary-bullets"><li>The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026.</li><li>Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.</li><li>If approved, Filspari would become the first treatment specifically indicated for FSGS, a rare kidney disorder.</li></ul>Shares of Travere Therapeutics (TVTX) and Ligand Pharmaceuticals (LGND) are drawing increased investor attention ahead of a key U.S. Food and Drug Administration decision on Filspari, a treatment for a rare kidney disease, expected on April 13.Ligand has a licensing agreement with Travere for Sparsentan, sold under the Filspari brand, under which Ligand will receive milestone payments and a 9% royalty on future global net sales of the drug.At the time of writing, <a href="https://stocktwits.com/symbol/TVTX">TVTX</a> and <a href="https://stocktwits.com/symbol/LGND">LGND</a> shares were little changed in pre-market trading on Friday.<h2 class="st-heading-2">FDA Did Not Seek Additional Information On Safety And Manufacturing</h2>In January, Travere Therapeutics announced that the FDA extended the review of its supplemental New Drug Application (sNDA) for Filspari in focal segmental glomerulosclerosis (FSGS), setting a Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026. The FDA did not request any additional information related to the drug’s safety or manufacturing.A PDUFA date is the FDA’s target date for making a decision on a drug application, which allows the drug to be marketed in the U.S.If approved, Filspari would become the first treatment specifically indicated for FSGS, a rare kidney disorder that can lead to progressive loss of kidney function and eventual kidney failure. Filspari is an oral, non-immunosuppressive therapy.<h2 class="st-heading-2">Citi Expects FDA Approval</h2>Last month, Citi maintained Travere Therapeutics’ ‘Buy’ rating and $48 price target. The firm expects the FDA to approve Filspari and added that the current share price does not fully reflect the company’s opportunity in FSGS.Travere’s Phase 3 study met its interim goal for proteinuria reduction but did not meet the primary kidney function endpoint. However, longer-term results showed the drug improved proteinuria, remission rates, and reduced progression to kidney failure, while remaining well-tolerated. Proteinuria is the high concentration of protein, usually albumin, in urine.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits was ‘bullish’ for TVTX and ‘neutral’ for LGND.One user expects TVTX stock to decline if there is no update before Friday’s close.<stembedurl>https://stocktwits.com/Smellmahass/message/649764886</stembedurl>However, another user expected a pre-FDA run-up to $32 - $35.<stembedurl>https://stocktwits.com/Buckeyeboy722/message/649091978</stembedurl>Year-to-date, TVTX shares have declined 20% while LGND stock has gained around 5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Travere Therapeutics, Ligand In Focus As FDA Set To Rule On Filspari Next Week – First FSGS Drug At Stake 

The FDA is expected to announce its decision on Filspari, a drug to treat focal segmental glomerulosclerosis, a type of kidney ailment.

TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari

Ligand Pharmaceuticals (NASDAQ:LGND) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ligand Pharmaceuticals stock on March 3rd...

Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND

Aberdeen Group plc cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 37.1% during the fourth quarter, according to the company in its most recent...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat.com reports. One...

Allspring Global Investments Holdings LLC Has $13.65 Million Position in Ligand Pharmaceuticals Incorporated $LGND

Allspring Global Investments Holdings LLC lessened its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 33.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,818...

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LGND News

LGNDLigand Pharmaceuticals, Inc. - Ordinary Shares - Class B